Developer docs
API playgroundTry for free, no card

Search company profiles

Avetabiomics

Full company profile

uuid0002w39

Namestring
Avetabiomics
Legal namestring
Aveta Biomics, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Aveta Biomics is a privately held, clinical-stage biotechnology company headquartered in Bedford, Massachusetts, founded in 2014 to develop first-in-class oral immunomodulatory cancer therapies based on its proprietary Orthologous Molecular Structures (OMS) platform. The OMS platform leverages evolutionary biology insights to design rational combinations of botanical molecules that are structurally and functionally similar to human endogenous metabolites, enabling multi-agent, multi-targeting drugs intended to address tumor molecular heterogeneity and prevent the evolution of drug resistance. The company's lead asset, APG-157, is an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC) — both as neoadjuvant therapy for resectable patients and induction/maintenance for unresectable patients — and is being evaluated across 50+ global clinical centers. APG-157 received FDA Fast Track Designation in August 2024 and is differentiated by a PD-L1-independent mechanism that targets both immunologically "hot" and "cold" tumors, with no Grade ≥3 treatment-related adverse events observed in Phase 2 trials to date.

The company has an early-stage pipeline beyond HNSCC: AMAX126 is a preclinical candidate for Diffuse Intrinsic Pontine Glioma (DIPG), and the platform is being explored in high-grade adult gliomas where Bevacizumab monotherapy is the current standard with poor outcomes. Aveta is pre-revenue and generates no product sales today; its distribution model for the investigational drug consists of a global clinical trial network and an FDA-compliant Expanded Access Program, with commercialization economics expected to flow through out-licensing or partnership upon regulatory approval. The company is led by CEO and co-founder Parag G. Mehta, PhD, alongside a C-suite drawn from Iovance Biotherapeutics, Sanofi, Genzyme, Agios Pharmaceuticals, and Servier, and a board featuring former Bristol-Myers Squibb CEO Peter R. Dolan, former SEC Chief Economist S.P. Kothari, and senior McKinsey healthcare partners. Scientific advisors include Harvard Professors Eugene Shakhnovich and Daniel Hartl.

Short descriptiontext

Aveta Biomics is a pre-revenue clinical-stage biotech developing first-in-class oral immunotherapies based on its Orthologous Molecular Structures (OMS) evolutionary biology platform; lead asset APG-157 is in a registrational Phase 3 trial for head and neck cancer with FDA Fast Track Designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunotherapy drug development, oncology clinical trials, oral cancer therapeutics, evolutionary biology platform, head and neck cancer
Industry1 code
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage oncology drug development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment. Revenue will be generated through drug commercialization upon regulatory approval.

avetabiomics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aveta Biomics is a clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment using its proprietary Orthologous Molecular Structures (OMS) platform. The platform leverages evolutionary biology to design multi-agent, multi-targeting drugs that address tumor molecular heterogeneity and prevent the evolution of drug-resistant cancers. Lead candidate APG-157 is in a registrational Phase 3 trial as neoadjuvant therapy for head and neck squamous cell carcinoma (HNSCC), working independently of PD-L1 status across both immunologically 'hot' and 'cold' tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2A trial demonstrated encouraging signals in event-free survival, disease control, ctDNA clearance, and tumor reduction
+3 more records
Product overview1 text field

Avetabiomics is a clinical-stage biotechnology company developing a new class of oral immunomodulatory therapies based on its Orthologous Molecular Structures (OMS) Platform. The company's lead product is APG-157, an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). APG-157 works independently of PD-L1 status, making it effective across both 'hot' and 'cold' tumors. The company also has AMAX126 in preclinical development for pediatric DIPG brain cancer, and is conducting preclinical studies in high-grade adult glioma. Their approach uses evolution-inspired combination therapeutics derived from botanical molecules that are structurally and functionally similar to human endogenous metabolites.

Product and service3 records
1APG-157
CategoryOncology drug candidate
Description

First-in-class oral immunomodulatory immunotherapy candidate designed to reprogram the tumor microenvironment. Works independently of PD-L1 status to target both 'hot' and 'cold' tumors by inducing selective apoptosis of cancer cells while simultaneously reprogramming the immune environment to prevent recurrence through arrest of cancer stem cells. Administered orally with topical application and systemic absorption through the oral cavity. Lead indication is head and neck squamous cell carcinoma (HNSCC).

2AMAX126
CategoryOncology drug candidate (preclinical)
Description

Novel mechanism drug candidate for Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive pediatric brain tumor typically diagnosed in children aged 5 to 10 with median survival of less than one year. In preclinical development with early evidence of efficacy.

3Orthologous Molecular Structures (OMS) Platform
CategoryDrug discovery platform
Description

Drug discovery platform based on insights into evolutionary biology that designs rational combinations of multifunctional botanical molecules called Orthologous Metabolite Structures (OMS). The platform addresses molecular heterogeneity of tumors and prevents evolution of drug-resistant cancers through evolutionary synergy among molecules and pleiotropic modulation of targets.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1VA Greater Los Angeles Healthcare System (VAGLAHS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Research collaboration with researchers from VA Greater Los Angeles Healthcare System for clinical investigation of APG-157 in head and neck squamous cell carcinoma. Joint presentation of Phase 2A subpopulation data at AACR 2026 demonstrating HPV viral load reduction and anti-tumor immunity activation.

avetabiomics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Developer of Keytruda (pembrolizumab), the dominant PD-1 inhibitor approved as standard of care in HNSCC. Direct competitive incumbent in Aveta's lead indication, though operating across a vastly broader oncology portfolio.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic immunotherapies for solid tumors including HNSCC. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC; Aveta's CMO previously worked at Replimune.

3Innate Pharma
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing innate immune system modulators (monoclonal antibodies, ADCs) for cancer treatment. Comparable as a clinical-stage biotech pursuing novel immunomodulatory mechanisms in oncology.

TypeDirect peer
Description

Clinical-stage oncology biotech developing antibody-drug conjugates and immunomodulators for solid tumors. Comparable clinical-stage immuno-oncology profile; Aveta's CBO previously served as CBO at Pyxis Oncology.

TypeDirect peer
Description

Developer of Libtayo (cemiplimab), a PD-1 inhibitor approved in HNSCC. Direct competitor in the same indication; Aveta's SVP Regulatory previously held senior roles at Regeneron.

TypeDirect peer
Description

Clinical-stage biotech developing MultiTAA-specific T cell therapies for HNSCC and other solid tumors. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC.

TypeDirect peer
Description

Clinical-stage biotech developing Immuno-STAT biologics that selectively modulate T cells for cancer, including HNSCC. Directly comparable as a clinical-stage immuno-oncology company with novel immunomodulatory approach.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Developer of Opdivo (nivolumab), approved for HNSCC and other cancers. Major immuno-oncology incumbent and notable because Aveta board member Peter Dolan is former CEO/Chairman of BMS.

TypeDirect peer
Description

Clinical-stage cell therapy biotech for solid tumors. Comparable as a clinical-stage oncology biotech with novel immunomodulatory mechanism; Aveta's CMO previously led clinical sciences at Iovance.

TypeDirect peer
Description

Clinical-stage oncology biotech developing tipifarnib for HRAS-mutant HNSCC. Direct peer in HNSCC drug development with similar stage and indication focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avetabiomics

Clinical-stage oncology drug developmentavetabiomics.com

Aveta Biomics is a pre-revenue clinical-stage biotech developing first-in-class oral immunotherapies based on its Orthologous Molecular Structures (OMS) evolutionary biology platform; lead asset APG-157 is in a registrational Phase 3 trial for head and neck cancer with FDA Fast Track Designation.

What Avetabiomics does

Aveta Biomics is a privately held, clinical-stage biotechnology company headquartered in Bedford, Massachusetts, founded in 2014 to develop first-in-class oral immunomodulatory cancer therapies based on its proprietary Orthologous Molecular Structures (OMS) platform. The OMS platform leverages evolutionary biology insights to design rational combinations of botanical molecules that are structurally and functionally similar to human endogenous metabolites, enabling multi-agent, multi-targeting drugs intended to address tumor molecular heterogeneity and prevent the evolution of drug resistance. The company's lead asset, APG-157, is an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC) — both as neoadjuvant therapy for resectable patients and induction/maintenance for unresectable patients — and is being evaluated across 50+ global clinical centers. APG-157 received FDA Fast Track Designation in August 2024 and is differentiated by a PD-L1-independent mechanism that targets both immunologically "hot" and "cold" tumors, with no Grade ≥3 treatment-related adverse events observed in Phase 2 trials to date.

The company has an early-stage pipeline beyond HNSCC: AMAX126 is a preclinical candidate for Diffuse Intrinsic Pontine Glioma (DIPG), and the platform is being explored in high-grade adult gliomas where Bevacizumab monotherapy is the current standard with poor outcomes. Aveta is pre-revenue and generates no product sales today; its distribution model for the investigational drug consists of a global clinical trial network and an FDA-compliant Expanded Access Program, with commercialization economics expected to flow through out-licensing or partnership upon regulatory approval. The company is led by CEO and co-founder Parag G. Mehta, PhD, alongside a C-suite drawn from Iovance Biotherapeutics, Sanofi, Genzyme, Agios Pharmaceuticals, and Servier, and a board featuring former Bristol-Myers Squibb CEO Peter R. Dolan, former SEC Chief Economist S.P. Kothari, and senior McKinsey healthcare partners. Scientific advisors include Harvard Professors Eugene Shakhnovich and Daniel Hartl.

Avetabiomics firmographics

Firmographics
Name
Avetabiomics
Legal name
Aveta Biomics, Inc.
Website
https://avetabiomics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Aveta Biomics is a pre-revenue clinical-stage biotech developing first-in-class oral immunotherapies based on its Orthologous Molecular Structures (OMS) evolutionary biology platform; lead asset APG-157 is in a registrational Phase 3 trial for head and neck cancer with FDA Fast Track Designation.
Ownership category
akta.pro rank

Avetabiomics industry classification

Industry
Product category
Clinical-stage oncology drug development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immunotherapy drug development
  • Oncology clinical trials
  • Oral cancer therapeutics
  • Evolutionary biology platform
  • Head and neck cancer

Where Avetabiomics is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avetabiomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment. Revenue will be generated through drug commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Avetabiomics product offering

Product offering

Core offering

Aveta Biomics is a clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment using its proprietary Orthologous Molecular Structures (OMS) platform. The platform leverages evolutionary biology to design multi-agent, multi-targeting drugs that address tumor molecular heterogeneity and prevent the evolution of drug-resistant cancers. Lead candidate APG-157 is in a registrational Phase 3 trial as neoadjuvant therapy for head and neck squamous cell carcinoma (HNSCC), working independently of PD-L1 status across both immunologically 'hot' and 'cold' tumors.

Product overview

Avetabiomics is a clinical-stage biotechnology company developing a new class of oral immunomodulatory therapies based on its Orthologous Molecular Structures (OMS) Platform. The company's lead product is APG-157, an oral immunotherapy in a registrational Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). APG-157 works independently of PD-L1 status, making it effective across both 'hot' and 'cold' tumors. The company also has AMAX126 in preclinical development for pediatric DIPG brain cancer, and is conducting preclinical studies in high-grade adult glioma. Their approach uses evolution-inspired combination therapeutics derived from botanical molecules that are structurally and functionally similar to human endogenous metabolites.

Differentiator

Problem solved

Functional benefit

Products and services

  • APG-157 First-in-class oral immunomodulatory immunotherapy candidate designed to reprogram the tumor microenvironment. Works independently of PD-L1 status to target both 'hot' and 'cold' tumors by inducing selective apoptosis of cancer cells while simultaneously reprogramming the immune environment to prevent recurrence through arrest of cancer stem cells. Administered orally with topical application and systemic absorption through the oral cavity. Lead indication is head and neck squamous cell carcinoma (HNSCC).
  • AMAX126 Novel mechanism drug candidate for Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive pediatric brain tumor typically diagnosed in children aged 5 to 10 with median survival of less than one year. In preclinical development with early evidence of efficacy.
  • Orthologous Molecular Structures (OMS) Platform Drug discovery platform based on insights into evolutionary biology that designs rational combinations of multifunctional botanical molecules called Orthologous Metabolite Structures (OMS). The platform addresses molecular heterogeneity of tumors and prevents evolution of drug-resistant cancers through evolutionary synergy among molecules and pleiotropic modulation of targets.

Quantifiable outcome

  • Phase 2A trial demonstrated encouraging signals in event-free survival, disease control, ctDNA clearance, and tumor reduction
  • +3 more outcomes

Companies that use Avetabiomics

Customer profile

Segments3 records

Ideal customer profiles2 records

Avetabiomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Avetabiomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • VA Greater Los Angeles Healthcare System (VAGLAHS)coreStrategic or Co-development Partner · 9 April 2026Research collaboration with researchers from VA Greater Los Angeles Healthcare System for clinical investigation of APG-157 in head and neck squamous cell carcinoma. Joint presentation of Phase 2A subpopulation data at AACR 2026 demonstrating HPV viral load reduction and anti-tumor immunity activation.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Avetabiomics competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Developer of Keytruda (pembrolizumab), the dominant PD-1 inhibitor approved as standard of care in HNSCC. Direct competitive incumbent in Aveta's lead indication, though operating across a vastly broader oncology portfolio.
  • Bristol-Myers Squibb: Developer of Opdivo (nivolumab), approved for HNSCC and other cancers. Major immuno-oncology incumbent and notable because Aveta board member Peter Dolan is former CEO/Chairman of BMS.

Direct peers

  • Replimune: Clinical-stage biotech developing oncolytic immunotherapies for solid tumors including HNSCC. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC; Aveta's CMO previously worked at Replimune.
  • Innate Pharma: Clinical-stage immuno-oncology company developing innate immune system modulators (monoclonal antibodies, ADCs) for cancer treatment. Comparable as a clinical-stage biotech pursuing novel immunomodulatory mechanisms in oncology.
  • Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunomodulators for solid tumors. Comparable clinical-stage immuno-oncology profile; Aveta's CBO previously served as CBO at Pyxis Oncology.
  • Regeneron Pharmaceuticals: Developer of Libtayo (cemiplimab), a PD-1 inhibitor approved in HNSCC. Direct competitor in the same indication; Aveta's SVP Regulatory previously held senior roles at Regeneron.
  • Marker Therapeutics: Clinical-stage biotech developing MultiTAA-specific T cell therapies for HNSCC and other solid tumors. Comparable as a clinical-stage immuno-oncology company pursuing novel mechanisms in HNSCC.
  • Cue Biopharma: Clinical-stage biotech developing Immuno-STAT biologics that selectively modulate T cells for cancer, including HNSCC. Directly comparable as a clinical-stage immuno-oncology company with novel immunomodulatory approach.
  • Iovance Biotherapeutics: Clinical-stage cell therapy biotech for solid tumors. Comparable as a clinical-stage oncology biotech with novel immunomodulatory mechanism; Aveta's CMO previously led clinical sciences at Iovance.
  • Kura Oncology: Clinical-stage oncology biotech developing tipifarnib for HRAS-mutant HNSCC. Direct peer in HNSCC drug development with similar stage and indication focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Avetabiomics social profiles

Digital presence

Avetabiomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avetabiomics leadership team

Management profile

Number of profiles

Profiles17 records

Avetabiomics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avetabiomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avetabiomics

What does Avetabiomics do?

Aveta Biomics is a clinical-stage biotechnology company developing first-in-class oral immunomodulatory therapies for cancer treatment using its proprietary Orthologous Molecular Structures (OMS) platform. The platform leverages evolutionary biology to design multi-agent, multi-targeting drugs that address tumor molecular heterogeneity and prevent the evolution of drug-resistant cancers. Lead candidate APG-157 is in a registrational Phase 3 trial as neoadjuvant therapy for head and neck squamous cell carcinoma (HNSCC), working independently of PD-L1 status across both immunologically 'hot' and 'cold' tumors.

Is Avetabiomics a public or private company?

Avetabiomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Avetabiomics founded?

Avetabiomics was founded in 2014. It employs 1 to 10 people.

Where is Avetabiomics based?

Avetabiomics is headquartered in Bedford, United States, in the North America region.

How does Avetabiomics make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are Avetabiomics's main competitors?

Broad incumbents on record are Merck & Co. and Bristol-Myers Squibb. Direct peers are Replimune, Innate Pharma, Pyxis Oncology, Regeneron Pharmaceuticals, Marker Therapeutics, Cue Biopharma, Iovance Biotherapeutics and Kura Oncology.

Does Avetabiomics have an API?

No public API is recorded for Avetabiomics.

What industry is Avetabiomics in?

Avetabiomics's product category is Clinical-stage oncology drug development. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OncLiveFDA Grants Fast Track Designation to Neoadjuvant APG-157 for Head and Neck CancerThe FDA has granted fast track designation to APG-157, a first-in-class botanical drug developed by Aveta Biomics, for the neoadjuvant treatment of head and neck cancer. This regulatory milestone accelerates the development pathway for the therapy, which is currently being evaluated in an ongoing phase 2 trial for locally advanced disease. The designation reflects the agency's recognition of the potential for meaningful treatment benefits in patients with poor survival odds under current standard-of-care options.Cancer NetworkFDA Grants Fast Track Status to Neoadjuvant APG-157 in Head and Neck CancerThe FDA has granted fast track designation to APG-157, an investigational immune-oncology agent developed by Aveta Biomics, for use as a neoadjuvant treatment in patients with head and neck cancer. This regulatory milestone accelerates the development of the orally administered lozenge, which is currently being evaluated in a phase 2 clinical trial to determine its efficacy in reducing tumor size and potentially lessening the need for extensive surgery.Clinical Trials ArenaNatera, Aveta Biomics collaborate on head and neck cancer trialNatera and Aveta Biomics have entered a strategic partnership to support Aveta's global Phase III AVTA 30-01 trial for the oral immunotherapy APG-157 in treating locally advanced head and neck squamous cell carcinoma. The collaboration will utilize Natera’s Signatera test to measure molecular residual disease, building on prior Phase II data that showed positive safety and survival outcomes. Patient enrollment is scheduled to commence in the second half of 2026 across multiple regions including Australia, Europe, and North America.DevdiscourseGlobal Health Updates: Partnerships, Approvals, and InnovationsThe Democratic Republic of Congo's health ministry reported that confirmed Ebola cases have reached 1,274 with 360 fatalities. In the pharmaceutical sector, Natera and Aveta Biomics formed a partnership for a late-stage head and neck cancer study, while the FDA considers reviewing Sandoz's generic GLP-1 drugs to compete with Eli Lilly.BioSpaceNatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck CancerNatera and Aveta Biomics announced a strategic partnership to support Aveta's global Phase 3 registrational trial of APG-157 for locally advanced head and neck squamous cell carcinoma. Under this agreement, Natera’s Signatera test will be utilized to evaluate molecular response and monitor minimal residual disease in approximately 826 patients across North America, Europe, Asia-Pacific, and Australia. The trial is expected to begin enrollment in the second half of 2026.MarketScreenerNatera, Inc. and Aveta Biomics, Inc. Announces Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck CancerNatera and Aveta Biomics announced a partnership supporting the global Phase 3 registrational trial AVTA 30-01 of APG-157 in locally advanced head and neck squamous cell carcinoma. The trial will enroll about 826 patients across multiple regions, with enrollment expected to begin in the second half of 2026.ContractpharmaNatera, Aveta Biomics Ink Partnership to Support Phase III Trial in Head and Neck CancerNatera and Aveta Biomics have entered a strategic partnership to support the upcoming Phase III clinical trial of Aveta’s immunotherapy drug APG-157 for locally advanced head and neck squamous cell carcinoma. The trial, which is scheduled to begin in the second half of 2026, will enroll over 800 patients across North America, Europe, Asia-Pacific, and Australia to evaluate molecular residual disease and treatment response. This collaboration builds on previous Phase II data showing favorable safety and tumor control outcomes for the first-in-class oral therapy.EIN PresswireAPG-157 Reduces HPV Viral Load and Activates Anti-Tumor Immunity in Head & Neck Cancer: Presentation at AACR 2026Aveta Biomics presented Phase 2A data on APG-157 at AACR 2026, showing reduced HPV16 viral load in HPV-positive head and neck cancer patients and activation of gigaxonin. The findings suggest a lower metastatic-risk phenotype and potential for other HPV-driven cancers.PR NewswireAveta Biomics and CSIR-CDRI Announce License to Aveta Biomics for the Development and Commercialization of First-in-Class Bone Health DrugsCSIR-Central Drug Research Institute (CDRI) in Lucknow, India, has granted Aveta Biomics of Boston, USA, an exclusive license to develop and commercialize CDRI's patented Caviunin-based drug compositions for bone health applications. The agreement represents a collaboration between an Indian government research institution and a US-based botanical drug developer. The article notes that osteoporosis affects one in three women and one in five men over age 50 globally.UCLA Samueli School of Engineering. Engineer Change.Botanical drug is shown to help patients with head and neck cancersA UCLA-led phase I clinical trial demonstrated that the botanical drug APG-157 effectively increased curcumin concentrations in tumor tissues and reduced inflammation markers in patients with head and neck cancers. The treatment showed no adverse effects while simultaneously attracting immune system T cells to tumors and reducing harmful bacterial abundance. Developed by Aveta Biomics under FDA guidance, this low-toxicity therapy may enhance the efficacy of existing immunotherapy drugs.